Molecular Partners AG Long Term Debt

Molecular Partners AG posts a long-term debt of $2.1M as of March 2026. That compares with $920K in the prior-year period — up 131.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Molecular Partners AG's long-term debt was $920K. The latest reading is $2.1M — a 131.2% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Molecular Partners AG's financial statement story. At $2.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MOLN's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Molecular Partners AG's other metric pages and overview cover the third.

Judging Molecular Partners AG against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $2.1M here, then scan peer and history charts to see if the gap is persistent.